Exon Skipping and Gene Therapy Research for LGMD2C
The Kurt+Peter Foundation funds advanced exon skipping and gene therapy research to develop new treatments for LGMD2C, supporting translational projects at top institutions.
Funder: Kurt+Peter Foundation
Due Dates: No open deadlines; funding is directed to selected researchers and institutions.
Funding Amounts: Varies by project; past grants have exceeded $800,000 for exon skipping research.
Summary: Supports innovative exon skipping and gene therapy research to develop treatments for LGMD2C.
Key Information: No open application process—funding is by direct invitation or selection.
Description
The Kurt+Peter Foundation is a 501(c)(3) non-profit organization dedicated to accelerating the development of effective therapies for limb-girdle muscular dystrophy type 2C (LGMD2C). The foundation funds cutting-edge research projects, including exon skipping studies at Northwestern University and gene therapy initiatives at Nationwide Children’s Hospital. By acting as a clinical sponsor and collaborating with top research institutions, the foundation aims to move promising scientific advances toward clinical application for LGMD2C patients.
